HQ Plasmid Center of Excellence based at UK life science hotspot now open for business.
Image Credit: Charles River Laboratories Inc.
To meet increasing demand for cell and gene therapies with accelerated clinical development, there is a need for manufacturers to rapidly supply phase-appropriate plasmid DNA, a critical starting material, to therapeutic developers.
We are delighted to announce the opening of a purpose-built plasmid contract development and manufacturing (CDMO) facility in Alderley Park.
With slots now available, with immediate project initiation, this Center of Excellence supports the growing need for High Quality (HQ) plasmid DNA which, manufactured to the principles of GMP, has the added benefit of an industry-leading 5+ week turnaround from initiation to release, reducing time to clinic.
On Thursday, October 20, 2022, together with key members of the cell and gene therapy community, we celebrated with an official ribbon cutting plus presentations by the team and a tour of the facility.
Charles River offers three grades of plasmid DNA, research, HQ and GMP, to smoothly navigate your program development journey.
With an established infrastructure and 20+ year track record, the Alderley Park site plays a key part in our mission to develop and expand our end-to-end capabilities in cell and gene therapy development, adding to a growing global network that will help expedite the process of bringing therapies to market.
Specifically, Alderley Park will enable our team to triple High-Quality plasmid DNA capacity to address global supply shortages and support our clients through rapid access to material.
The new 16,000 square foot facility expands our capabilities and will help fast-track the process of bringing therapies to market, address global supply shortages and support therapeutic developers through rapid access to material. As new gene therapies are launched around the world with the potential to change lives, our investment is a further vote of confidence in the future of this exciting and transformative industry here in the UK.
Niall Dinwoodie, Executive Director, Gene Manufacturing Europe
HQ Plasmid DNA Manufacture
We understand that therapeutic developers are faced with the challenge of driving development timelines to clinical manufacturing. Our HQ plasmid production service combines critical features of GMP manufacturing with rapid turnaround times to support the clinical manufacturing of viral vectors, including AAV and lentivirus for use in immuno-oncology and CRISPR-based therapies.
Our phase-appropriate approach supports a seamless transition through your program development journey. For more information please visit: Plasmid DNA Manufacturing Services.